OneSource Specialty Pharma Ltd: CDMO Cinderella or Just a P/E Pumpkin?

1. At a Glance

A loss-making biologics CDMO trading at 283x earnings with a 740% revenue explosion. Backed by Strides Pharma. Promoters selling. FDA approvals incoming. Risky? Oh absolutely. Interesting? Very.

2. Introduction with Hook

Imagine you’re in a biotech jungle. In one corner, big pharma is roaring. In another, a nimble gazelle named OneSource is sprinting—bruised, bleeding cash, but gaining speed.

• TTM Sales Growth: +740% (yes, you read that right)
• TTM Net Profit: -₹18 Cr, but last quarter? A surprise +₹98 Cr profit!
• Market Cap: ₹23,134 Cr with just ₹1,445 Cr in annual sales. Yikes?

So, are we looking at India’s version of Lonza or another bubble waiting to deflate?

3. Business Model (WTF Do They Even Do?)

OneSource is a CDMO—Contract Development and Manufacturing Organisation. Their job? Help big pharma and biotech firms make biologics and injectable drugs.

Revenue Engines:

• R&D services
• Clinical development
• Technology transfer
• Regulatory support
• Commercial-scale biologics manufacturing

Key USP?
They ride the biologics wave, targeting the €23 billion biosimilar market globally. Also, they’re GMP-certified by Brazil (ANVISA), with USFDA inspections cleared (with VAI classification).

In short:
OneSource = Labcoat + Scalability + Compliance + Global ambition.

4. Financials Overview

Let’s be real. They’re just exiting their burn phase.